Top Markets
Coin of the day
NuGenerex Immuno-Oncology, Inc. NuGenerex Immuno-Oncology, Inc.

NuGenerex Immuno-Oncology, Inc.

NUGX
Rangering i aksjer #41797
NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating... NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating cancer through the strategic modulation of the immune system. The company's development pipeline includes a range of immunotherapeutic products and vaccines. Notably, it is advancing AE37, a peptide immunotherapeutic vaccine, which is currently undergoing Phase II clinical studies for metastatic triple-negative breast cancer. Founded in 1993 and headquartered in Miramar, Florida, the entity was formerly named Antigen Express, Inc. NuGenerex Immuno-Oncology, Inc. operates as a subsidiary of Generex Biotechnology Corporation.
Aksjekurs
$0.0001
Sist synkronisert: 2023-05-22
Markedsverdi
$10.03K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel NuGenerex Immuno-Oncology, Inc. (NUGX)

Kategori

EPS for NuGenerex Immuno-Oncology, Inc. (NUGX)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til NuGenerex Immuno-Oncology, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for NuGenerex Immuno-Oncology, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter